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Small inhibitor of Bcl-2, HA14-1, selectively enhanced the
apoptotic effect of cisplatin by modulating Bcl-2 family members
in MDA-MB-231 breast cancer cells
Elif Damla Arisan Æ Ozgur Kutuk Æ Tugsan Tezil Æ Cagri Bodur Æ
Dilek Telci Æ Huveyda Basaga
Abstract Inhibition or downregulation of Bcl-2 represents
a new therapeutic approach to by-pass chemoresistance in
cancer cells. Therefore, we explored the potential of this
approach in breast cancer cells. Cisplatin and paclitaxel
induced apoptosis in a dose-dependent manner in MCF-7
(drug-sensitive) and MDA-MB-231 (drug-insensitive) cells.
Furthermore, when we transiently silenced Bcl-2, both cis-
platin and paclitaxel induced apoptosis more than parental
cells. Dose dependent induction of apoptosis by drugs was
enhanced by the pre-treatment of these cells with HA14-1, a
Bcl-2 inhibitor. Although the effect of cisplatin was signif-
icant on both cell lines, the effect of paclitaxel was much less
potent only in MDA-MB-231 cells. To further understand
the distinct role of drugs in MDA-MB-231 cells pretreated
with HA14-1, caspases and Bcl-2 family proteins were
studied. The apoptotic effect of cisplatin with or without
HA14-1 pre-treatment is shown to be caspase-dependent.
Among pro-apoptotic Bcl-2 proteins, Bax and Puma were
found to be up-regulated whereas Bcl-2 and Bcl-xL were
down-regulated when cells were pretreated with HA14-1
followed by paclitaxel or cisplatin. Enforced Bcl-2 expres-
sion in MDA-MB-231 cells abrogated the sensitizing effect
of HA14-1 in cisplatin induced apoptosis. These results
suggest that the potentiating effect of HA14-1 is drug and
cell type specific and may not only depend on the inhibition
of Bcl-2. Importantly, alteration of other pro-apoptotic or
anti-apoptotic Bcl-2 family members may dictate the
apoptotic response when HA14-1 is combined with che-
motherapeutic drugs.
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Introduction
Apoptosis is regulated by the complex interactions between
two groups of Bcl-2 family members: pro-apoptotic pro-
teins (Bax/Bak-like proteins and BH3-only proteins) and
anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL, Mcl-1). The
mechanistic actions of pro-apoptotic and anti-apoptotic
Bcl-2 proteins have been proposed to antagonize each other
through heterodimerization in mitochondrial apoptotic
regulation [1]. Bcl-2 inhibits mitochondrial permeabiliza-
tion, which is induced by pro-apoptotic Bax, and Bak, and
subsequent cell death. The functional inhibition of Bax or
Bak by Bcl-2 relies, in part, on the ability of Bcl-2 to bind
to the conserved BH3-domain of pro-apoptotic Bcl-2
family proteins through its hydrophobic cleft. Bcl-2 also
sequesters activator BH3-domain proteins (Bid and Bim)
and blocks the activation of Bax and Bak. Following death
stimuli, sensitizer BH3-only proteins (Bad, Bmf, Puma,
Noxa, Bik) displace Bax or Bak or activator BH3-only
proteins from their anti-apoptotic partner to promote cell
death [2, 3].
Apoptosis is the primary mechanism that causes many
malign cells to die when subjected to chemotherapy or
radiotherapy. However, resistant clones exist by the
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overexpression of anti-apoptotic proteins such as Bcl-2 and
Bcl-xL. It is implicated in chemoresistance mechanism, as
overexpression of Bcl-2 may inhibit apoptosis induced by
many of the currently available anticancer drugs [4, 5]. The
targeting of anti-apoptotic function of Bcl-2 in tumor cells
is an attractive strategy for either restoring the normal
apoptotic process or making these cells more susceptible to
chemotherapy or radiotherapy [3].
Widely used anticancer drugs including cisplatin and
paclitaxel exert their toxicity generally through induction
of apoptosis. Both drugs have distinct mechanism through
by which the activating apoptotic response occurs through
their chemical properties. Paclitaxel is a mitotic blocker by
stabilizing microtubules whereas cisplatin is a platinum
derived chemotherapeutic agent that triggers DNA damage.
Although they induce apoptosis, chemoresistance is a
major obstacle in the cancer therapy.
Ethyl-2-amino-6-cyclopentyl-4-(1-cyano-2-ethoxy-2-
oxoethyl)-4H-chromone-3-carboxylate (HA14-1), the first
reported small molecule antagonist for Bcl-2 protein, was
identified by Wang et al. [5]. This simple chemical struc-
ture is a putative Bcl-2 inhibitor, which was identified from
in silico screens. HA14-1 disrupts the binding interaction
of the Bak BH3-domain peptide with Bcl-2 and Bcl-xL
proteins [4], strongly inhibits the Bcl-2/Bax interaction [6],
and also inhibits the interaction between Bcl-2 and BH3-
only protein Bim [7]. Since its discovery, HA14-1 has been
shown to enhance the cytotoxic effects of variety of anti-
cancer agents.
In the present study, we demonstrated that transiently
silencing of Bcl-2 increased the apoptotic effect of cisplatin
and paclitaxel in both cell lines. Chemical inhibition of
Bcl-2 by HA14-1 enhanced the apoptosis induced by cis-
platin or paclitaxel in MCF-7 cells. However, pre-treatment
of HA14-1 significantly enhanced the apoptosis induced by
cisplatin in MDA-MB-231 cells and paclitaxel was found
to be much less potent. This selective sensitizing effect of
HA14-1 was shown to be via modulation of other pro or
anti-apoptotic Bcl-2 family members. This is the first study
that reveals the selective action of HA14-1 on the apoptotic
response of cancer cells when combined with chemother-
apeutic drugs.
Materials and methods
Chemicals, antibodies and primers
Bcl-2 inhibitor HA14-1 [ethyl-2-amino-6-bromo-4-(lcy-
ano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate],
was purchased from Calbiochem. Solutions of HA14-1
were freshly prepared before each experiment (dissolved in
DMSO as 5 mM stock). Paclitaxel was dissolved in ethanol
to make a 7.2 mM stock solution and stored at 4C.
Cisplatin was provided by Bristol Myers Squibb as 3.3 mM
solution. G418 (Sigma) was prepared as a 50 mg/ml stock
solution and kept at 4C in aseptic conditions.
The pan-caspase inhibitor (Z-VAD-FMK), caspase-3
inhibitor (Z-DEVD-FMK) and caspase-9 inhibitor (Z-LEHD-
FMK) were purchased from BD Biosciences.
Anti-Bcl-2 (1:1,000), Bcl-xL (1:2,000), Bax (1:2,000),
Puma (1:1,000), b-actin (1:2,000) were purchased from cell
signaling technology (CST). HRP-conjugated secondary
anti-rabbit antibody (1:5,000) was from CST. Anti PARP
and cleaved PARP, cleaved caspase-3 and pro-caspase-3,
cleaved caspase-9 and pro-caspase-9 (each 1:1,000) were
from CST. The appropriate primers for quantitative
RT-PCR experiments were purchased from Geneglobe
(Qiagen).
Cell culture and stable cell line
MCF-7 (HTB-22, ATCC) and MDA-MB-231 cells (HTB-
26, ATCC) were maintained in RPMI1640 (Biological
Industries) with 2 mM L-glutamine, 10% fetal calf serum
(Pan Biotech), 1% nonessential amino acids (Biological
Industries), and 100 U/100 mg ml-1 penicillin/streptomy-
cin (Biological Industries) and grown in the presence of 5%
CO2 in humidified air at 37C.
For establishing stable cell lines, MDA-MB-231 cells
were transfected using FugeneHD (Roche) with 3 lg
plasmid pCI-neo alone (Promega) and pCI-neo-Bcl-2
according to the manufacturer’s instructions. The G418-
resistant (700 lg/ml) clones were analyzed for Bcl-2
expression by qRT-PCR.
Cell viability assay
Cells were seeded in 96-well plates and incubated for 24 h
with various concentrations of cisplatin (0–250 lM), pac-
litaxel (0–100 nM) and Bcl-2 specific inhibitor HA14-1
(0–10 lM). Cell viability was determined by colorimetric
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bro-
mide (Sigma) assay, which is based on the conversion of
MTT to MTT-formazan by mitochondrial enzymes.
Absorbance was determined at 570 nm with a Biorad
microplate reader.
M30 apoptosense ELISA assay
Cytokeratin-18 cleavage indicates the activation of casp-
ases and was measured using reagents from Peviva AB.
MCF-7 and MDA-MB-231 breast cancer cells were seeded
on 96-well plates. A solution of 10% NP-40 was added and
mixed for 5 min at room temperature. Two replicates of
25 ll cell lysate/medium were transferred into a specific
M30 Apoptosense ELISA assay. This assay was performed
according to the manufacturer’s instructions. After the
washing step, stop solution was added to each well, and
samples were incubated in the dark for 5 min. The spec-
trophotometric measurement was made at 450 nm.
RNA extraction and reverse transcriptase assay
Total RNA was isolated using a trizol reagent (Invitrogen)
following the procedure described by the manufacturer.
Total RNA was digested with RNase-free DNase (Boeh-
ringer Mannheim) for 15 min at 37C.
Reverse transcription (RT) was performed using a spe-
cific RT kit (Sensiscript, Qiagen). The RT reaction mixture
contained 1 ll of total RNA, 500 ng of oligo(dT) primer,
59 RT reaction buffer, 10 mM dNTPs, and 200 U of a
reverse transcriptase (Qiagen) in a total volume of 20 ll.
All samples were incubated at 37C for 1 h. The quantity
of cDNA was calculated using spectrophotometry by
determination of optical density at 260 nm (OD260). Purity
was calculated using the OD260/280 ratio.
Transfection of siRNA
MCF-7 and MDA-MB-231 cells were placed in a six well
plate 24 h prior to transfection. Cells were transfected with
20 nM Hs_Bcl-2_9_siRNA (Qiagen-Gene Globe) using 1:6
ratio siRNA specific transfection reagent (RNAifect, Qia-
gen) following the manufacturer’s protocol. After 48 h
incubation, the silencing effect was checked with qRT-
PCR and western blot analysis.
Real time RT-PCR
Real-time PCR was performed in 96-well 0.2 ml thin wall
PCR plates using the iCycler Thermal Cycler (Bio-Rad)
and carried out using the QuantiTect SYBR Green PCR
Master Mix (Qiagen), which contained HotStarTaq DNA
Polymerase, QuantiTect SYBR Green PCR Buffer, and
SYBR Green I. The real-time PCR reaction mixture
contained 19 QuantiTect SYBR Green PCR Master Mix,
0.3 mM primer pairs, and 500 ng cDNA in a total volume
of 25 ll. The mixture was heated initially at 95C for
15 min to activate the HotStarTaq DNA Polymerase and
then this was followed by 40 cycles of denaturation at
94C for 1 min, annealing at 50–54C for 1 min, and
extension at 72C for 1 min. Furthermore, the number of
amplified products was identified by melt curve analysis.
The melt curve protocols designed for increment tem-
peratures of 0.5C with a starting temperature of 45C
and ending at 90C were repeated to ensure that primer
dimers and other nonspecific products had been mini-
mized or eliminated.
Immunoblot analysis
MCF-7 and MDA-MB-231 cells were treated with the
appropriate concentrations of drugs. First, all samples were
washed with ice-cold PBS and lysed on ice in a solution
containing 20 mM Tris–HCl (pH 7.5), 150 mM NaCl,
Nonidet P-40 0.5%, (v/v), 1 mM EDTA, 0.5 mM PMSF,
1 mM DTT, protease inhibitor cocktail (Complete, Roche).
After cell lysis, cell debris was removed by centrifugation
for 15 min at 13,200g, and protein concentrations were
determined with a Bradford protein assay. Total protein
lysates (30 lg) were separated on a 12% SDS–PAGE and
transferred onto PVDF membranes. The membranes were
then blocked with 5% milk blocking solution in Tris buffer
saline (TBS)-Tween20 and incubated with appropriate
primary and horseradish peroxidase (HRP)-conjugated
secondary antibodies (CST) in antibody buffer containing
5% (v/v) milk blocking solution. After washes with TBS-
Tween 20, proteins were analyzed using an enhanced
chemiluminescence detection system (ECL or ECL-
Advance, Amersham Pharmacia Biotech) and exposed to
Hyperfilm-ECL (Amersham Pharmacia Biotech).
Statistical analysis
All samples were evaluated statistically using an excel
calculation file. Relative expression of mRNA was shown
as mean ± standard deviation, and the student’s t-test was
applied to understand the probability efficiency. Differ-
ences were regarded as statistically significant at values of
P \ 0.05.
Results
Cisplatin and paclitaxel induces apoptosis
We used MCF-7 (p53 wt) and MDA-MB-231 (p53 mt)
breast cancer cells to investigate whether cisplatin or
paclitaxel decreases cell viability through the induction of
apoptosis.
To assess the cytotoxic effect of cisplatin or paclitaxel,
we treated MCF-7 and MDA-MB-231 cells at various
concentrations of these drugs for 24 h and we assessed the
cell viability using MTT assay. Since moderate cytotoxic
effects were observed at 30 lM cisplatin and 20 nM pac-
litaxel (30 and 15% decrease in cell viability in MCF-7
cells and 29 and 23% decrease in cell viability in MDA-
MB-231 cells, respectively; Fig. 1a–b), these concentra-
tions were used in further experiments.
To confirm that the decrease in cell viability was indeed
due to apoptosis, we performed the M30 Apoptosense
ELISA assay (Fig. 1c). A 30 lM cisplatin increased M30
antigen levels by 2.5- and 1.9-fold in MCF-7 and MDA-
MB-231 cells, respectively. We determined that 20 nM
paclitaxel increased 2.1- and 1.6-fold M30 antigen levels
compared to the control samples in both cell lines,
respectively (drug vs. control **P \ 0.01).
Bcl-2 siRNA enhances drug induced apoptosis
in MCF-7 and MDA-MB-231 cells
The efficiency of Bcl-2 siRNA on Bcl-2 protein levels was
assessed at 24 and 48 h following transfection. Transfection
of Bcl-2 siRNA markedly down-regulated Bcl-2 within
48 h. We did not detect any effect of scramble siRNA on
Bcl-2 protein levels (Fig. 2a). Transfection ratio was
determined as 1:6 for siRNA: transfection reagent complex.
To investigate if treatment with Bcl-2 siRNA itself had
any effect on cell viability, we performed the MTT assay
after 48 h transfection. The results here (Fig. 2b) showed
that Bcl-2 siRNA did not decrease cell viability. When
transfection of Bcl-2 siRNA was followed by treatment
with cisplatin, cell viability further reduced by 52 and 65%
in MCF-7 and MDA-MB-231 cells, compared to treatment
with scramble siRNA and cisplatin, respectively. Similarly,
transfection of Bcl-2 siRNA followed by treatment with
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Fig. 1 Determination of drug induced cytotoxic response and
apoptosis. a and b The cytotoxic effect of cisplatin or paclitaxel
was determined by MTT assay following exposure of MCF-7 and
MDA-MB-231 cells to drugs for 24 h, respectively. These results
represent the mean (±SEM) values obtained from at least two
different assays (with three different cell cultures). c Determination of
drug induced apoptosis by M30 Apoptosense ELISA assay. MCF-7
and MDA-MB-231 cells were grown up on 96 well plates, respec-
tively. Cells were treated with 30 lM cisplatin or 20 nM paclitaxel
for 24 h. The concentration of M30 antigen is presented as Units per
Liter (U/l). Each experiment was repeated three times from two
different cell culture experiments
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Fig. 2 Silencing of Bcl-2 by siRNA enhanced drug induced
apoptosis. a Bcl-2 siRNA silencing effect and efficient transfection
reagent complex ratio was determined by western blotting. b Cell
viability was determined by MTT assay. After silencing, MCF-7 and
MDA-MB-231 breast cancer cells were treated with 30 lM cisplatin
or 20 nM paclitaxel for 24 h. c Apoptotic cell death was determined
by M30 assay in drug exposed MCF-7 and MDA-MB-231 cells
following silencing of Bcl-2. NS is scramble siRNA
paclitaxel, reduced cell viability by 43 and 57% in both cell
lines, compared to treatment with scramble siRNA and
paclitaxel, respectively. These findings were consistent
with a possible increase in apoptosis and we performed
M30 Apoptosense ELISA assay. Down-regulation of Bcl-2
by siRNA resulted in increased apoptotic response by
chemotherapeutic drugs. As demonstrated in Fig. 2c, each
chemotherapeutic drug induced M30 antigen levels due to
apoptotic cell death more than parental cells in the tran-
siently Bcl-2 down-regulated cells (P \ 0.05). This
indicates that siRNAs for Bcl-2 sensitized cells to both
cisplatin and paclitaxel.
HA14-1 selectively sensitizes MCF-7 and
MDA-MB-231 cells to apoptosis induced
by cisplatin and paclitaxel
Since anti-apoptotic Bcl-2 family members likely contrib-
ute to the resistance in cancer chemotherapy by raising the
threshold for apoptosis, we investigated whether the addi-
tion of HA14-1 would potentiate the apoptotic induction by
chemotherapeutics. Initially we determined dose dependent
effect of HA14-1 on MCF-7 and MDA-MB-231 cells. Cells
were exposed to various concentrations of HA14-1 for 24 h
(Fig. 3a–d) and cell viability was determined by MTT
assay.
HA14-1, between 1 and 5 lM concentrations for MCF-7
cells and between 1 and 8 lM concentrations for MDA-
MB-231 cells did not significantly decrease cell viability in
both cell lines as compared to control (P [ 0.05). Whereas
HA14-1 (10 lM) reduced cell viability by 22 and 15% in
MCF-7 and MDA-MB-231 cells, respectively (P \ 0.05;
Fig. 3a–d). We found out that pre-treatment of HA14-1
markedly enhanced the cytotoxic effect of cisplatin or
paclitaxel as compared to drug alone treatment in MCF-7
cells (Fig. 3a–b). However, HA14-1 (10 lM) pre-treatment
followed by cisplatin significantly increased the cytotoxic
effect of cisplatin by 41% (Fig. 3c; P \ 0.05; cisplatin vs.
HA14-1 plus cisplatin), 10 lM HA14-1 pre-treatment did
not enhance the cytotoxic effect of paclitaxel in MDA-MB-
231 cells (paclitaxel vs. HA14-1 plus paclitaxel; Fig. 3d,
P [ 0.05).
These findings were also confirmed with M30 Apopto-
sense ELISA assay which determines apoptotic cell
populations. Pre-treatment of 10 lM HA14-1 followed by
30 lM cisplatin increased M30 antigen concentration by
3.7- and 2.9-fold in MCF-7 and MDA-MB-231 cells as
compare to cisplatin alone, respectively (P \ 0.05). How-
ever, pre-treatment of 10 lM HA14-1 followed by 20 nM
paclitaxel treatment significantly increased apoptosis by
3.1-fold in MCF-7 cells (P \ 0.05), by contrast pre-treat-
ment of 10 lM HA14-1 followed by 20 nM paclitaxel
treatment did not significantly increased M30 antigen
levels as compared to paclitaxel alone in MDA-MB-231
cells (1.9- vs. 2.0-fold; P [ 0.05; Fig. 3e).
In order to understand the effect of HA14-1 on Bcl-2
expression, we determined Bcl-2 protein levels following
HA14-1 treatment. As shown in Fig. 3f 10 lM HA14-1 did
not alter total amount of Bcl-2 at different time points
within 24 h of treatment.
HA14-1 pre-treatment potentiates cisplatin-induced
apoptosis
To investigate whether drug-induced apoptosis is mediated
by caspases, the proteolytic activation of caspase-3 was
examined in drug-insensitive MDA-MB-231 cells. As
shown in Fig. 4a. Pre-treatment of cells with HA14-1 fol-
lowed by paclitaxel induced cleavage of pro-caspase-3 to
active form (p19/p17). Whereas paclitaxel alone did not
trigger caspase-3 activation. Cisplatin in the presence or
absence of HA14-1 was able to induce cleavage of caspase-
3. Engagement of apoptosis is further confirmed by the
detection of PARP degradation. HA14-1 increased the
paclitaxel- and cisplatin-induced PARP cleavage as
opposed to drug treatment-only cases. Caspase-9 was also
activated by chemotherapeutics. Of note, pre-treatment
with HA14-1 followed by cisplatin or paclitaxel treatment
induced cleavage of pro-caspase-9 (Fig. 4a).
In our experimental system, we used pan-caspase
inhibitor (z-VAD-fmk), caspase-3 inhibitor (z-DEVD-
fmk) and caspase-9 inhibitor (z-LEHD-fmk) to address
the significance of caspase activation. Cells were
exposed to these inhibitors for 1 h. After this, cells were
pre-treated with HA14-1 followed by cisplatin or treated
with only cisplatin 24 h (Fig. 4b). Cytotoxicity was
evaluated by MTT assay.
Treatment with caspase inhibitors, each at 20 lM con-
centration, prevented cytotoxic effects of cisplatin and
HA14-1 plus cisplatin. These findings suggest that the
synergistic effect of HA14-1 with cisplatin was caspase-
dependent (Fig. 4b).
HA14-1 pre-treatment followed by cisplatin
or paclitaxel modulates the expression
of Bcl-2 family members
Bcl-2 exerts a significant part of its survival function by
physically interacting with pro-apoptotic members of Bcl-2
family. Therefore we next analyzed the mRNA levels of
Bcl-2, Bax, Bcl-xL and Puma in MDA-MB-231 cells
treated with cisplatin, paclitaxel, HA14-1, HA14-1 plus
cisplatin and HA14-1 plus paclitaxel. Pre-treatment of
HA14-1 followed by cisplatin downregulated Bcl-2
expression more than threefold whereas this ratio was
determined as twofold in cells pretreated HA14-1 followed
by paclitaxel as compared to cells treated with paclitaxel
alone (Fig. 5a). These findings were verified by
immunoblotting results. Pre-treatment of HA14-1 followed
by cisplatin led to sharp decrease in Bcl-2 protein levels
(Fig. 5b).
0
20
40
60
80
100
120
Control 2µM 5µM 8µM 10µM
R
el
at
iv
e 
ce
ll 
v
ia
bi
lit
y 
(%
)
HA14-1
30 mM Cis
HA14-1+30 mM Cis
0
20
40
60
80
100
120
Control 2µM 5µM 8µM 10µM
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
 
(%
)
HA14-1
20 nM Pac
HA14-1+20nM Pac
0
20
40
60
80
100
120
Control 2µM 5µM 8µM 10µM
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
 
(%
)
HA14-1
30 uM Cis
HA14-1+30uM Cis
A B
C
D
HA14-1 Concentration
HA14-1 Concentration
HA14-1 Concentration
HA14-1 Concentration
0
20
40
60
80
100
120
Control 2µM 5µM 8µM 10µM
R
el
at
iv
e 
ce
ll 
v
ia
bi
lit
y 
(%
)
HA14-1
20 nM Pac
HA14-1+ Pac
0h       2h       4h         8h      12h     24h
Bcl-2
β-actin
E
F
0
5
10
15
20
25
Co
nc
en
tra
tio
n
 o
f M
30
 a
n
tig
en
 (U
/L) MCF-7 MDA-MB-231
MCF-7
MDA-MB-231
HA14-1 - + - -
Cisplatin - - + -
Paclitaxel - - - +
Fig. 3 Sensitizing effect of HA14-1 is drug and cell type specific. a
and c MCF-7 and MDA-MB-231 cells were treated with cisplatin
(30 lM), various concentrations of HA14-1 (0–10 lM) and their
combinations. Cell viability was evaluated by MTT assay. Columns
represent the mean (±SEM) values obtained from at least two
different assays (with three different cell cultures), each comprising
six replicates. b and d MCF-7 and MDA-MB-231 cells were exposed
to paclitaxel (20 nM), various concentrations of HA14-1 (0–10 lM)
and their combinations. Cell viability was checked by MTT assay.
Columns represent the mean (±SEM) values obtained from at least
two different assays (with three different cell cultures), each
comprising six replicates. e MCF-7 and MDA-MB-231 cells were
treated with HA14-1 alone or pre-treated with HA14-1 followed by
cisplatin or paclitaxel. Apoptotic responses were determined by M30
Apoptosense ELISA assay. The concentration of M30 antigen is
presented as Units per Liter (U/L). Each experiment was replicated
three times from two different cell culture experiments. f The
modulation of Bcl-2 expression within 24 h time interval in 10 lM
HA14-1 exposed breast cancer cells. b-actin was used as loading
control
Bcl-xL mRNA and protein levels were markedly
decreased by cisplatin and paclitaxel treatment as com-
pared to control. Pre-treatment of cells with HA14-1 alone
also downregulated Bcl-xL protein levels, even more
drastically than cisplatin or paclitaxel treated cells. Of note,
treatment with HA14-1 led to a decrease in Bcl-xL mRNA
levels similar to treatment with cisplatin and paclitaxel.
Treatment of cells with HA14-1 plus cisplatin or HA14-1
plus paclitaxel resulted in decrease in Bcl-xL mRNA and
protein levels (Fig. 5a–b).
Treatment of MDA-MB-231 cells with cisplatin or
paclitaxel resulted in increased levels of Bax mRNA and
protein. In addition, pre-treatment of cells with HA14-1
followed by cisplatin or paclitaxel further increased the
expression of Bax mRNA and protein levels.
Treatment with cisplatin induced Puma mRNA and
protein levels as compared to control, whereas paclitaxel
exert a similar effect. Of note, treatment with HA14-1
alone increased Puma mRNA and protein expression.
Further increase in Puma mRNA and protein expression
was observed when cells were pre-treated with HA14-1
followed by treatment with cisplatin or paclitaxel.
Bcl-2 over-expression prevents cytotoxic effect
of cisplatin
To establish the role of Bcl-2 overexpression in drug
induced apoptosis we set up stable Bcl-2 overexpressing
MDA-MB-231 cells following G418 selection. Bcl-2
overexpression was determined by qRT-PCR and immu-
noblotting results (Fig. 6a). Next we investigated the
sensitizing effect of HA14-1 on cisplatin induced cell death
in MDA-MB-231 Bcl-2 overexpressing cells. As shown in
Fig. 6b, cisplatin induced cell viability loss by 21% after
72 h of treatment, whereas pre-treatment of HA14-1 failed
to exert additional cytotoxic effect and decreased cell
viability by 27% when combined with cisplatin treatment
(drug vs. combined treatment P [ 0.05).
Discussion
Resistance to anticancer therapy is a complex problem in
both clinical and molecular oncology. Several studies
established that over-expression of anti-apoptotic Bcl-2
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curve of b-actin. These values
are normalized by dividing with
b-actin. The data were
represented mean ± SD and
representative of independent
two experiments, and each
experiment was repeated three
times. b Thirty micrograms total
protein lysate was subjected to
western blots with antibodies
directed against the Bcl-2
family members. b-actin was
used as loading control
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Fig. 6 Bcl-2 overexpression abrogated cisplatin induced apoptosis. a
MDA-MB-231 cells were transfected with Bcl-2 plasmid and selected
with G418 (700 lg/ml). Bcl-2 mRNA copy number were calculating
using standard curve of b-actin. Selected clones were verified by
western blotting. b The determination of cell viability in MDA-MB-
231Bcl-2? breast cancer cells. MDA-MB-231Bcl-2? breast cancer
cells were pre-treated with HA14-1 followed by cisplatin for 72 h
family proteins confers resistance to apoptosis and
decreases efficiency of therapeutics [2, 3]. Since pro-
apoptotic Bcl-2 family proteins dock into the BH1-BH2
groove of anti-apoptotic members via their BH3-domain, it
has been proposed that BH3 mimetics antagonize the anti-
apoptotic members. Currently, a favored strategy for Bcl-2
antagonism is based on small molecules that target Bcl-2
anti-apoptotic proteins by mimicking a BH3 domain [1].
Hence, several compounds have been isolated or chemi-
cally synthesized, showing different binding specificity and
affinity for these proteins and promoting apoptosis.
Among them, HA14-1, is a BH3 mimetic compound,
involves changes in Ca2? homeostasis, inhibition of
mitochondrial potential, Bax translocation, reactive oxygen
species generation (ROS), cytochrome c release and cas-
pase-9/-3 activation, and subsequently poly(ADP-ribose)
polymerase (PARP) cleavage [4, 5, 8–12]. The therapeutic
effect of HA14-1 has been described in a variety of tumor
cells. HA14-1 cooperates with other drugs such as flavo-
piridol, bortezomib, dexamethasone, doxorubicin and
cytrabine [13–18]. Additionally, HA14-1 could potentiate
non-toxic MAPK inhibitors as lethal agents in the cell
culture environment [19].
In this study, we determined that cisplatin and paclitaxel
exerted distinct modes of action in inducing apoptosis and
this effect being cell type specific. Cisplatin and paclitaxel-
induced apoptosis is promoted in Bcl-2 silenced MCF-7
and MDA-MB-231 cells more than parental cells (Fig. 2b–
c). Therefore we conclude that Bcl-2 is an attractive target
for novel treatment strategies of breast carcinoma.
Pre-treatment of HA14-1 significantly potentiated the
effect of both drugs in MCF-seven cells. In MDA-MB 231
cells, although pre-treatment of HA14-1 potentiated effect
of cisplatin significantly, sensitization was much less when
cisplatin was replaced by paclitaxel (Fig. 3c, P \ 0.05;
Fig. 3d, P [ 0.05). These results were further confirmed by
M30 Apoptosense ELISA assay which determines caspase-
induced cytokeratine 18 cleavage in apoptotic cell popu-
lations (Fig. 3e). Additionally, Bcl-2 protein level was
checked but not found to be altered by exposure to HA14-1
(Fig. 3f). Neither caspase-9 nor PARP cleavage were found
to be drug specific (Fig. 4a) indicating that cisplatin
(30 lM) or paclitaxel (20 nM) induced mitochondrial
apoptotic pathway in MDA-MB-231 cells. Although cis-
platin with or without pre-treatment with HA14-1
increased the cleavage of caspase-3, paclitaxel did not
exert same effect in MDA-MB-231 cells. During this
process, paclitaxel-induced caspase-3 cleavage is inde-
pendent from caspase-9 activation. It is also possible that
paclitaxel acts via activation of another effector caspase,
like caspases-6 or -7, or by an unrelated pathway. Previ-
ously, the possible involvement of caspase-7 in paclitaxel-
induced apoptosis has been suggested in human esophageal
squamous cancer cells and in non-small-cell lung cancer
H460 and H520 cell lines [20, 21]. Although pre-treatment of
HA14-1 followed by paclitaxel activated caspase-3, HA14-1
did not markedly increase the apoptotic effect of paclitaxel in
MDA-MB-231 cells. In order to understand the different
sensitizing effects of HA14-1 pre-treatment of paclitaxel,
further studies should focus on other effector caspases, or
caspase independent cell death mechanisms. We also
established that cytotoxic effects of cisplatin or HA14-1 plus
cisplatin were prevented by pan-caspase, caspase-9 and
caspase-3 inhibitors (Fig. 4b). Thus, we conclude that cis-
platin-induced apoptosis occurs by caspase dependent
pathways. Consistent with our findings, pan-caspase, cas-
pase-9 and caspase-3 inhibitors prevented HA14-1-induced
apoptosis in follicular lymphoma B cells [22].
Bcl-2, Bcl-xL, and Bax have been implicated as major
regulators in the control of mitochondrial apoptotic path-
way. Bcl-2 and Bcl-xL bind to outer membrane of
mitochondria and block cytochrome c efflux. In contrast,
upon apoptosis induction, Bax translocates from cytosol to
mitochondria where it enhances cytochrome c release
through either down-regulation of Bcl-2/Bcl-xL and/or up-
regulation of Bax [2, 3]. We presented here, HA14-1 pre-
treatment followed by cisplatin or paclitaxel abrogated Bcl-
2 and Bcl-xL in MDA-MB-231 cells albeit greater extends
with cisplatin (Fig. 5a–b). HA14-1 drastically down-regu-
lated Bcl-xL expression in our experimental model
(Fig. 5a–b). Therefore, altered ratio of pro-apoptotic and
anti-apoptotic Bcl-2 family members might be an impor-
tant key question to understand the sensitizing effect of
HA14-1 in MDA-MB-231 cells. Of note, phosphorylation
of Bcl-2 has been implicated as an important regulatory
mechanism of its function and is a common event in
response to anti-mitotic drugs. Recent studies have
revealed that this post-translational modification may be
necessary for Bcl-2’s full and potent anti-apoptotic func-
tion. Paclitaxel treatment activates members of the JNK/
SAPK MAPK family, which then disable Bcl-2 through
phosphorylation within its flexible loop region. Although
paclitaxel can also bind to the loop of Bcl-2 protein, its
significance is unclear. It is possible that alterations in the
loop region of Bcl-2 could account for some cases of
paclitaxel-resistance contrast to other mitotic blockers [23].
Thereby, further investigation of paclitaxel induced Bcl-2
phosphorylation and related up-stream events might be
informative.
Previous studies pointed out that, lack of Bax might
cause failure to respond to HA14-1 [8]. Hence, determi-
nation of the Bax expression and related events in HA14-1-
exposed cell lines might be significant in characterization
of drug specific sensitizing effect of HA14-1. We herein
demonstrated that Bax was markedly up-regulated by pre-
treatment of HA14-1 followed by cisplatin or paclitaxel
(Fig. 5a–b). Moreover, pre-treatment of HA14-1 followed
by cisplatin induced Bax translocation to mitochondria
MDA-MB-231 cells (unpublished data).
Considering the finding that cisplatin or paclitaxel
induced apoptosis in MDA-MB-231 cells which have
lacking functional p53, we can conclude that apoptosis
induction by both drugs do not require p53 transcriptional
activity in consistent with previous reports. Additionally,
Puma, a BH3-only protein, is a transcriptional target of
p53-mediated apoptosis signaling. It is also an important
mediator of apoptosis and induced by a number of che-
motherapeutics and radiation [24, 25]. Puma acts by
modulating Bax activity through binding to Bcl-xL and
dissociate the interaction of Bax and Bcl-xL to facilitate
cytochrome c release from the mitochondria, thereby trig-
gering the apoptotic cascade [26]. It was previously
demonstrated that p53-independent Puma up-regulation
might be playing role in cisplatin-induced apoptosis in
colon cancer cells [27]. Over-expression of Puma induces
disorganization/disruption of the cellular microtubule net-
work in apoptotic fibroblasts [28]. Therefore, microtubules
displayed de-polymerized and dispersed structures
throughout the cytoplasm. In contrast to the mechanistic
action of Puma, paclitaxel and docetaxel induce stabiliza-
tion of microtubule formation and lead to subsequent cell
death. As shown in Fig. 5a–b, while cisplatin (30 lM) was
up-regulating Puma mRNA and protein expression, pac-
litaxel (20 nM) did not up-regulate Puma expression in
MDA-MB-231 cells. Based on this result, we conclude that
cisplatin and HA14-1 induce p53-independent Puma up-
regulation in MDA-MB-231 cells, whereas paclitaxel
failed to up-regulate Puma. Interestingly, cisplatin-induced
apoptosis was not observed in Bcl-2 over-expressing
MDA-MB-231 cells. Similarly, resistance to cisplatin was
determined in p53 deficient cells which have up-regulated
Bcl-2 or Bcl-xL [29]. Hence, we conclude that p53-inde-
pendent mechanisms which were activated by cisplatin in
MDA-MB-231 cells could be successfully abrogated by
Bcl-2. However, pre-treatment of HA14-1 did not increase
the apoptotic effect of cisplatin in Bcl-2 over-expressing
MDA-MB-231 cells (Fig. 6b). In previous reports, the
synergistic effect of HA14-1 with SP600125 which is a
specific inhibitor of c-Jun N-terminal kinase in U937 Bcl-2
over-expressing cells was found to be dose dependent [16].
Therefore, higher doses of HA14-1 might be more effective
to enhance cisplatin-induced apoptosis in Bcl-2 over-
expressing cells.
Briefly, we demonstrated that down-regulation of Bcl-2
by siRNA potentiated cytotoxic effects of cisplatin and
paclitaxel in both cell lines, whereas chemical inhibition of
Bcl-2 promoted cisplatin and to a much lesser extend
paclitaxel-induced cell death in MDA-MB-231 cells. The
sensitizing effect of HA14-1 through the induction of
apoptosis was found to be drug and cell type specific. The
treatment of MDA-MB-231 cells by cisplatin activated
p53-independent mitochondrial apoptotic pathway through
induction of caspase-3 and overcame Bcl-2-mediated pro-
tection in functional p53 lacking cells. However, Bcl-2
over-expression confers resistance to cisplatin. Pre-treat-
ment with HA14-1 followed by cisplatin markedly down-
regulated Bcl-2 and Bcl-xL and up-regulated BH3-only
protein Bax and Puma. As pro- and anti-apoptotic Bcl-2
proteins are in balance for controlling the mitochondrial
apoptotic pathway, their ratio is indicative for apoptotic
response. Previous findings and those in our study provide
a strong biological rationale for using HA14-1 in combi-
nation with therapeutic options. According to these all
findings, pre-treatment of HA14-1 followed by cisplatin
has potential as a novel therapeutic approach in breast
carcinoma.
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